Palbociclib, a drug recently approved by the FDA to treat advanced breast cancer, may have potential for a for a type of thyroid cancer known as papillary thyroid carcinoma. This form of cancer commonly develops a resistance to treatment, in particular the medication vemurafenib. Oncotarget researchers have discovered that by combining the 2 medications they were able to slow cell division that was previously undeterred by vemurafenib alone. Previous research had indicated that in vemuafenib reisitant cells, modification of a certain gene slowed down the division of these cells, palbociclib may have the potential to emulate this process giving hope for those who have developed a resistance to the current PTC treatments on the market. Check the journal at SCImago Journal & Country Rank.
Cancer research encompasses many fields and many discoveries meant to treat certain forms of cancer end up showing potential for treatment relevant to other forms. Oncotarget’s research extends across the board to a plethora of different cancer topics. This dedication to cures and treatments was apparent at 2017’s Frontiers in Cancer Science where Oncotarget awarded 4 different international researchers located in India and Italy. The topics of the winners’ presentations ranged from kidney cancer to Mesothelioma with focus on processes that could contribute to the advancement of many types of cancer treatments. Download output styles at Endnote.com
2017’s Frontiers in Cancer Research was hosted by 7 internationally known research institutions in Singapore from November 6-8th. “The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe,” states Oncotarget editor-in-chief, Mikhail Blagosklonny. Through travel sponsorships and research grants, Oncotarget’s devotion to ensuring the spread of knowledge in the field of caner research is greatly assisted by participation in events such as FCS help assure that one day there will be hope for anyone with a positive diagnosis of cancer.
Seattle Genetics is one of the leading biotech companies with its headquarters in Bothell Cascade Business Park. The giant biotech company is located in a seemingly quiet area, with no major scientific sophistications on the outside. In fact, as you head towards the headquarters, you will hardly believe if there could be a giant biotech company in that location. But as you get inside to building three, there is a huge green triangular sculpture that looks like it is made of Lego bricks. The triangular sculpture is a simplified model of a human antibody.
The massive sculpture is enough to alert even a stranger of what goes on behind the closed doors. It was founded in 1998. The antibodies manufactured by Seattle Genetics helps to deliver a toxic payload into a cancer cell, which helps to destroy it from the inside. The company has huge ambitions of becoming the largest and the most efficient biotech company both locally and internationally. Seattle Genetics currently boasts of having a market value that has hit the $10 billion mark and with close to 1000 employees on its payroll. The company hopes to soon graduate from a biotech firm that it is today to a huge pharmaceutical company.
The company has invested largely in research as they strive to bring more innovative ideas and products to the market. Seattle Genetics has also been involved in aggressive marketing to bring more customers aboard. As part of its growth strategy, Seattle Genetics expects to bring in more talent to its pool as they seek to hire some more 200 employees this year. In 2016, the firm is reported that it collected a whopping $418 million, which is 46 percent up from what it collected in 2014. Seattle’s stock price has shot from $20 a share to $66, which is a triple factor. Although Seattle Genetics is yet to record profit, the recent growth trajectory is very promising to investors and the general public.
About Clay Siegall
Dr. Clay Siegall is the co-founder of Seattle Genetics. He co-founded the firm 18 years ago, and he currently serves as the President, the CEO and Chairman of the Board. Clay Siegall is a trained scientist with a focus on targeted cancer therapies. Dr. Siegall built Seattle Genetics on a firm ground of rigorous research, innovation, and drug production practices that has catapulted the organization to its current status.